^1,2Amala Institute of Medical Sciences, Thrissur-680555, Kerala, INDIA.

Email: edwin_edzz@yahoo.co.in, venma.mampilly@gmail.com

REFERENCES

1. Vigersky R, Shrivastav M: Role of continuous glucose monitoring for type 2 in diabetes management and research. J Diabetes Complications 2017;31:280–287
2. Vigersky RA, Fonda SJ, Chellappa M, et al. : Short-and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 2012;35:32–38.
3. Fonda SJ, Graham C, Munakata J, et al. : The cost-effectiveness of real-time continuous glucose monitoring (RT-CGM) in type 2 diabetes. J Diabetes Sci Technol 2016;10:898–904.
4. Maurizi AR, Pozzilli P: Do we need continuous glucose monitoring in type 2 diabetes? Diabetes Metab Res Rev 23 August 2013; doi: 10.1002/dmrr.2450.
5. Poolsup N, Suksomboon N, Kyaw AM: Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes. Diabetol Metab Syndr 2013;5:39.
6. Pepper GM: Hemoglobin A1c values and CGM response. Diabetes Technol Ther 2012;14:972.
7. Beck RW, Riddlesworth T, Ruedy K, et al. : Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND Randomized Clinical Trial. JAMA2017;317:371–378.
8. Zick R, Petersen B, Richter M, Haug C: Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with type 2 diabetes on multiple daily insulin injection therapy. Diabetes Technol Ther 2007;9:483–492.
9. Pazos-Couselo M, García-López JM, González-Rodríguez M, et al. : High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study. Can J Diabetes 2015;39:428–433.
10. Klimontov VV, Myakina NE: Glucose variability indices predict the episodes of nocturnal hypoglycemia in elderly type 2 diabetic patients treated with insulin. Diabetes & Metabolic Syndrome: Clinical Research & Reviews2017;11:119–124.
11. Gómez AM, Umpierrez GE, Muñoz OM, et al. : Continuous glucose monitoring versus capillary point-of-care testing for inpatient glycemic control in type 2 diabetes patients hospitalized in the general ward and treated with a basal bolus insulin regimen. J Diabetes Sci Technol 2016;10:325–329.
12. Kovatchev B, Cobelli C: Glucose variability: timing, risk analysis, and relationship to hypoglycemia in diabetes.Diabetes Care 2016;39:502–510.
13. FLAT-SUGAR Trial Investigators: Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk. Diabetes Care 2016;39:973–981.
14. Bajaj HS, Venn K, Ye C, et al. : Lowest glucose variability and hypoglycemia are observed with the combination of a GLP-1 receptor agonist and basal insulin (VARIATION Study). Diabetes Care 2017;40:194–200
15. FDA: Diabetes outcome measures beyond hemoglobin A1c: CDER Public Workshop. Paper presented at: Diabetes Outcome Measures Beyond Hemoglobin A1c: CDER Public Workshop; August29, 2016; Silver Spring, MD
16. Abbott: FreeStyle Libre Pro. FreeStyle Libre Pro 2017. 
17. Abbott: FreeStyle Libre Flash. FreeStyle Libre Flash 2017. 
18. Haak T, Hanaire H, Ajjan R, et al. : Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther 2016;8:1–19.
19. Medtronic: iPro^®2 Professional CGM. iPro^®2 Professional CGM 2017.
20. Dexcom I: Professional CGM. Professional CGM 2017.